NCT02424344 - Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients | Biotech Hunter

Enrollment

267

Participants

Timeline

Start Date

April 27, 2015

Primary Completion Date

July 25, 2016

Study Completion Date

July 25, 2016

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Aclidinium/Formoterol

Aclidinium bromide/Formoterol fumarate FDC 400/12μg dry powder for oral inhalation twice daily via Genuair inhaler

DRUG

Placebo

Dose-matched placebo dry powder for oral inhalation twice daily via Genuair inhaler

Trial Locations (26)

1125

Research Site, Budapest

2045

Research Site, Törökbálint

4400

Research Site, Nyíregyháza

6772

Research Site, Deszk

7740

Research Site, Jena

10003

Research Site, Cáceres

10117

Research Site, Berlin

10717

Research Site, Berlin

10787

Research Site, Berlin

10969

Research Site, Berlin

13086

Research Site, Berlin

20253

Research Site, Hamburg

20354

Research Site, Hamburg

22927

Research Site, Großhansdorf

23552

Research Site, Lübeck

28046

Research Site, Madrid

30173

Research Site, Hanover

44263

Research Site, Dortmund

60596

Research Site, Frankfurt

65187

Research Site, Wiesbaden

80331

Research Site, München

L8N 3Z5

Research Site, Hamilton

K7L 2V7

Research Site, Kingston

G1V 4G5

Research Site, Sainte-Foy

S7N 0W8

Research Site, Saskatoon

03004

Research Site, Alicante